The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Phase II trial in progress: ASTX727 ± venetoclax in newly diagnosed MDS/MPN
Rory Shallis, MD, Yale Cancer Center, New Haven, CT, introduces the ongoing Phase II VICTORY MDS/MPN trial (NCT05600894), evaluating the efficacy of ASTX727 (oral decitabine-cedazuridine) monotherapy and ASTX727 with venetoclax in patients with newly diagnosed myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). The trial focuses on establishing complete response (CR) rates, with secondary endpoints including overall survival (OS) and measurable residual disease (MRD) outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, Curio Science, Servier, Rigel, Gilead Sciences
